- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 239/20 - Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
Patent holdings for IPC class C07D 239/20
Total number of patents in this class: 55
10-year publication summary
3
|
3
|
5
|
6
|
4
|
2
|
4
|
2
|
2
|
2
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
VALO Health, Inc. | 175 |
5 |
Enanta Pharmaceuticals, Inc. | 429 |
4 |
Bristol-myers Squibb Company | 4855 |
3 |
Takeda Pharmaceutical Company Limited | 2706 |
3 |
Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | 185 |
2 |
Paratek Pharmaceuticals, Inc. | 112 |
2 |
Universite de Montreal | 341 |
2 |
The Walter and Eliza Hall Institute of Medical Research | 165 |
2 |
Certest Biotec, S.L. | 27 |
2 |
Janssen Sciences Ireland Unlimited Company | 400 |
2 |
Merck Sharp & Dohme LLC | 3757 |
2 |
BASF SE | 20991 |
1 |
Merck Sharp & Dohme Corp. | 2191 |
1 |
Commissariat à l'énergie atomique et aux energies alternatives | 10946 |
1 |
Allergan Sales, LLC | 253 |
1 |
Astex Therapeutics Limited | 242 |
1 |
Beijing Molecule Science and Technology Co., Ltd. | 12 |
1 |
Cristalia Produtos Quimicos Farmaceuticos Ltda. | 27 |
1 |
Doosan Corporation | 433 |
1 |
Epizyme, Inc. | 374 |
1 |
Other owners | 17 |